836 Results
Sort By:
Published on June 4, 2019
In advance of three scheduled hearings this week and next in front of the intellectual property subcommittee of the Senate Judiciary Committee, an American Civil Liberties Union (ACLU) coalition of more than 100 organizations from medical, scientific, patient advocacy, and women’s health groups today sent a letter to Capitol Hill…
Published on May 31, 2019
Bayer AG and Foundation Medicine announced a global collaboration for the development and commercialization of NGS-based companion diagnostics, that will cut across multiple oncology drug candidates and approved therapies developed by Bayer. The deal covers Foundation Medicine’s full portfolio of tests, including its flagship offering FoundationOne CDx. Financial terms of…
Published on May 30, 2019
Former Foundation Medicine president and COO Steven Kafka, Ph.D., has joined with current and former colleagues to launch a cancer liquid biopsy developer focused on detecting multiple cancers at earlier stages, with $110 million in Series A financing—the largest-ever investment by a licensee of a technology developed at Johns Hopkins…
Published on May 30, 2019
Researchers at the University of Edinburgh and the European Bioinformatics Institute at the European Molecular Biology Laboratory (EMBL-EBI) have introduced a new diagnostic genome-wide sequence analysis software that significantly improves evaluating genetically heterogeneous clinical presentations. This new tool can identify specific genetic changes in the three billion base pairs of…
Published on May 28, 2019
A team of Princeton University-led researchers has used an artificial intelligence algorithm to identify mutations in “junk” DNA that can cause autism. The findings, reported in Nature Genetics, are the first to functionally link mutations in regulatory DNA with a complex disease such as autism, and suggest that the alterations…
Published on May 24, 2019
It’s an aspirational goal: develop a simple blood test that can detect cancer cells in an asymptomatic patient, locate the tissue of origin, and give that person an early diagnosis when treatment is more likely to be successful. The ideal test would be able to do all that and do…
Published on May 13, 2019
More than 67 actionable clinical discoveries were made through deep longitudinal genomic analysis by a group led by Michael Snyder, MD, chair of the genetics department at Stanford University. The Stanford group’s pioneering precision health study is published in the May issue of Nature Medicine. To carry out the study,…
Published on May 9, 2019
Personalized treatment, guided by the Oncotype DX test, could lower the initial cost of early breast cancer care in the United States by approximately $50 million in the first year of its application, according to a new study published in JNCI. April 24, 2019. The study was conducted by Georgetown Lombardi…
Published on April 29, 2019
Canopy Biosciences, a provider of gene editing and gene expression products and services, has acquired Zellkraftwerk for an undisclosed price, in a deal designed to expand the buyer into a “multi-omics” company offering genomics expertise with cell and tissue analysis solutions. By expanding its gene editing and genomics analysis portfolio…
Published on April 26, 2019
Regional, non-profit healthcare delivery network AdventHealth (formerly Adventist Health System) announced it will partner with personal genomics company Helix to screen up to 10,000 patients for familial hypercholesterolemia (FH), an inherited condition that can lead to high cholesterol levels and potentially serious health problems. The AdventHealth program, called WholeMe, is…
Published on April 25, 2019
Researchers at Rady Children’s Institute for Genomic Medicine (RCIGM) have built an automated pipeline designed to deliver a potential diagnosis in record time for hospitalized children suspected of having rare genetic diseases. The pipeline required minimal user intervention, increased usability, and shortened the time to diagnosis, delivering a provisional finding in…
Published on April 15, 2019
Precision cancer treatments have improved patient survival rates by targeting underlying molecular drivers of disease, but only for those with commonly known mutations like BRCA1/2. Now researchers at Harvard Medical School have devised an algorithm to target such treatments to patients without these telltale mutations. The algorithm examines patterns of…
Published on April 15, 2019
Using miniature laboratory-grown tumors known as patient-derived organoids (PDOs) as models of colorectal cancer (CRC), researchers at The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in the U.K. have found that CRC tumors can switch off expression of a cell surface molecule that is a key…
Published on April 11, 2019
Precision Therapeutics’ wholly-owned subsidiary, Helomics announced it will collaborate with SpeciCare, whereby Helomics will provide CRO services and its D-CHIP artificial intelligence (AI) platform for a functional precision medicine study called PIONEER sponsored by SpeciCare. Georgia-based SpeciCare is a cryopreservation company that saves living tumor tissue which it says can…
Published on April 8, 2019
Five years after the introduction of the $1,000 genome, the sequencing field remains rife with chatter about pushing the cost much lower—not only to $100 (and why the world may not be ready for it), but as far down as $10. Coming close to that $100 benchmark last year was Veritas Genetics.…